{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:51:45Z","timestamp":1781106705664,"version":"3.54.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,27]]},"DOI":"10.7759\/cureus.76478","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T18:27:51Z","timestamp":1735324071000},"source":"Crossref","is-referenced-by-count":1,"title":["Cutaneous Manifestations of Systemic Lupus Erythematosus and Their Correlation With Cardiac Involvement"],"prefix":"10.7759","author":[{"given":"Romasa","family":"Zeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Valentina Combariza","family":"Chinome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taranpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machineni Meghana","family":"Chowdary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Jeanette","family":"Manzanares Vidals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunjida","family":"Mehnaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres Felipe Torres","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanthi Sarayu","family":"Gadde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raaj Pawan Kumar","family":"Lingamgunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2022.09.005","article-title":"Cutaneous lupus erythematosus: A review of etiopathogenic, clinical, diagnostic and therapeutic aspects","volume":"98","author":"Vale EC","year":"2023","unstructured":"Vale EC, Garcia LC. Cutaneous lupus erythematosus: A review of etiopathogenic, clinical, diagnostic and therapeutic aspects. An Bras Dermatol. 2023, 98:355-72. 10.1016\/j.abd.2022.09.005","journal-title":"An Bras Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa382","article-title":"Long-term outcomes in systemic lupus erythematosus: Trends over time and major contributors","volume":"59","author":"Arnaud L","year":"2020","unstructured":"Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: Trends over time and major contributors. Rheumatology (Oxford). 2020, 59:v29-38. 10.1093\/rheumatology\/keaa382","journal-title":"Rheumatology (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis A","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021, 80:14-25. 10.1136\/annrheumdis-2020-218272","journal-title":"Ann Rheum Dis"},{"key":"ref4","article-title":"Systemic Lupus Erythematosus","author":"Vaillant AAJ","year":"2024","unstructured":"Vaillant AAJ, Goyal A, Varacallo M. Systemic Lupus Erythematosus. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2013.07.008","article-title":"Cutaneous lupus erythematosus: Diagnosis and treatment","volume":"27","author":"Okon LG","year":"2013","unstructured":"Okon LG, Werth VP. Cutaneous lupus erythematosus: Diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013, 27:391-404. 10.1016\/j.berh.2013.07.008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.53189","article-title":"Cutaneous manifestations of systemic lupus erythematosus in a tertiary referral center","volume":"54","author":"Kole AK","year":"2009","unstructured":"Kole AK, Ghosh A. Cutaneous manifestations of systemic lupus erythematosus in a tertiary referral center. Indian J Dermatol. 2009, 54:132-6. 10.4103\/0019-5154.53189","journal-title":"Indian J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2200oa","article-title":"Cardiac involvement in systemic lupus erythematosus","volume":"14","author":"Doria A","year":"2005","unstructured":"Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005, 14:683-6. 10.1191\/0961203305lu2200oa","journal-title":"Lupus"},{"key":"ref8","article-title":"Pericardial Effusion","author":"Willner DA","year":"2024","unstructured":"Willner DA, Goyal A, Grigorova Y, Sharma S, Kiel J. Pericardial Effusion. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref9","article-title":"Libman-Sacks Endocarditis","author":"Ibrahim AM","year":"2024","unstructured":"Ibrahim AM, Siddique MS. Libman-Sacks Endocarditis. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000358","article-title":"Cardiac manifestations of systemic lupus erythematous: An overview of the incidence, risk factors, diagnostic criteria, pathophysiology and treatment options","volume":"30","author":"Zagelbaum Ward NK","year":"2022","unstructured":"Zagelbaum Ward NK, Linares-Koloffon C, Posligua A, et al.. Cardiac manifestations of systemic lupus erythematous: An overview of the incidence, risk factors, diagnostic criteria, pathophysiology and treatment options. Cardiol Rev. 2022, 30:38-43. 10.1097\/CRD.0000000000000358","journal-title":"Cardiol Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102211","article-title":"Psoriasis and cardiovascular comorbidities: Focusing on severe vascular events, cardiovascular risk factors and implications for treatment","volume":"18","author":"Hu SC","year":"2017","unstructured":"Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: Focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017, 18:2211. 10.3390\/ijms18102211","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.176","article-title":"Genetic susceptibility to systemic lupus erythematosus in the genomic era","volume":"6","author":"Deng Y","year":"2010","unstructured":"Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010, 6:683-92. 10.1038\/nrrheum.2010.176","journal-title":"Nat Rev Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030506","article-title":"Epigenetic alterations in immune cells of systemic lupus erythematosus and therapeutic implications","volume":"11","author":"Adams DE","year":"2022","unstructured":"Adams DE, Shao WH. Epigenetic alterations in immune cells of systemic lupus erythematosus and therapeutic implications. Cells. 2022, 11:506. 10.3390\/cells11030506","journal-title":"Cells"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016427","article-title":"The effect of prolactin on immune cell subsets involved in SLE pathogenesis","volume":"13","author":"Legorreta-Haquet MV","year":"2022","unstructured":"Legorreta-Haquet MV, Santana-S\u00e1nchez P, Ch\u00e1vez-S\u00e1nchez L, Ch\u00e1vez-Rueda AK. The effect of prolactin on immune cell subsets involved in SLE pathogenesis. Front Immunol. 2022, 13:1016427. 10.3389\/fimmu.2022.1016427","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.235122","article-title":"Neutrophil extracellular traps in autoimmune diseases","volume":"131","author":"He Y","year":"2018","unstructured":"He Y, Yang FY, Sun EW. Neutrophil extracellular traps in autoimmune diseases. Chin Med J (Engl). 2018, 131:1513-9. 10.4103\/0366-6999.235122","journal-title":"Chin Med J (Engl)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1279","article-title":"Autoantibodies against complement component C1q in systemic lupus erythematosus","volume":"10","author":"Trendelenburg M","year":"2021","unstructured":"Trendelenburg M. Autoantibodies against complement component C1q in systemic lupus erythematosus. Clin Transl Immunology. 2021, 10:e1279. 10.1002\/cti2.1279","journal-title":"Clin Transl Immunology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac140","article-title":"Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease","volume":"33","author":"Tanaka Y","year":"2023","unstructured":"Tanaka Y, Kusuda M, Yamaguchi Y. Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease. Mod Rheumatol. 2023, 33:857-67. 10.1093\/mr\/roac140","journal-title":"Mod Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1147447","article-title":"Differential impact of environmental factors on systemic and localized autoimmunity","volume":"14","author":"Touil H","year":"2023","unstructured":"Touil H, Mounts K, De Jager PL. Differential impact of environmental factors on systemic and localized autoimmunity. Front Immunol. 2023, 14:1147447. 10.3389\/fimmu.2023.1147447","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2021.04.006","article-title":"B cells in systemic lupus erythematosus: From disease mechanisms to targeted therapies","volume":"47","author":"Canny SP","year":"2021","unstructured":"Canny SP, Jackson SW. B cells in systemic lupus erythematosus: From disease mechanisms to targeted therapies. Rheum Dis Clin North Am. 2021, 47:395-413. 10.1016\/j.rdc.2021.04.006","journal-title":"Rheum Dis Clin North Am"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcreue.2022.10.006","article-title":"Interstitial lung disease in systemic lupus erythematosus: State of the art search","volume":"31","author":"Santacruz JC","year":"2024","unstructured":"Santacruz JC, Mantilla MJ, Rodr\u00edguez-Salas G, Rueda I, Santos AM, Londo\u00f1o J. Interstitial lung disease in systemic lupus erythematosus: State of the art search. Rev Colomb Reumatol Engl Ed. 2024, 31:234-242. 10.1016\/j.rcreue.2022.10.006","journal-title":"Rev Colomb Reumatol Engl Ed"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39284","article-title":"Systemic lupus erythematosus and cardiovascular diseases: A systematic review","volume":"15","author":"Nor MA","year":"2023","unstructured":"Nor MA, Ogedegbe OJ, Barbarawi A, et al.. Systemic lupus erythematosus and cardiovascular diseases: A systematic review. Cureus. 2023, 15:e39284. 10.7759\/cureus.39284","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22027","article-title":"Systemic lupus erythematosus and cardiovascular disease","volume":"14","author":"Jha SB","year":"2022","unstructured":"Jha SB, Rivera AP, Flores Monar GV, et al.. Systemic lupus erythematosus and cardiovascular disease. Cureus. 2022, 14:e22027. 10.7759\/cureus.22027","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1452678","article-title":"Pathological mechanisms and crosstalk among various cell death pathways in cardiac involvement of systemic lupus erythematosus","volume":"15","author":"Wei J","year":"2024","unstructured":"Wei J, Wang A, Li B, et al.. Pathological mechanisms and crosstalk among various cell death pathways in cardiac involvement of systemic lupus erythematosus. Front Immunol. 2024, 15:1452678. 10.3389\/fimmu.2024.1452678","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21698","article-title":"A review of cardiac manifestations in patients with systemic lupus erythematosus and antiphospholipid syndrome with focus on endocarditis","volume":"14","author":"Tayem MG","year":"2022","unstructured":"Tayem MG, Shahin L, Shook J, Kesselman MM. A review of cardiac manifestations in patients with systemic lupus erythematosus and antiphospholipid syndrome with focus on endocarditis. Cureus. 2022, 14:e21698. 10.7759\/cureus.21698","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104639","article-title":"Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study","author":"Olbrich H","year":"2023","unstructured":"Olbrich H, Kridin K, Zirpel H . Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study. EBioMedicine. 2023, 10.1016\/j.ebiom.2023.104639","journal-title":"EBioMedicine"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2021.8804","article-title":"Lupus-related vasculitis in a cohort of systemic lupus erythematosus patients","volume":"36","author":"Gamal SM","year":"2021","unstructured":"Gamal SM, Mohamed SS, Tantawy M, Siam I, Soliman A, Niazy MH. Lupus-related vasculitis in a cohort of systemic lupus erythematosus patients. Arch Rheumatol. 2021, 36:595-692. 10.46497\/ArchRheumatol.2021.8804","journal-title":"Arch Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010150","article-title":"Myocarditis and chronic inflammatory cardiomyopathy, from acute inflammation to chronic inflammatory damage: An update on pathophysiology and diagnosis","volume":"13","author":"Uccello G","year":"2023","unstructured":"Uccello G, Bonacchi G, Rossi VA, Montrasio G, Beltrami M. Myocarditis and chronic inflammatory cardiomyopathy, from acute inflammation to chronic inflammatory damage: An update on pathophysiology and diagnosis. J Clin Med. 2023, 13:150. 10.3390\/jcm13010150","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/his.14440","article-title":"Cutaneous manifestations of lupus erythematosus: A practical clinicopathological review for pathologists","volume":"80","author":"Bitar C","year":"2022","unstructured":"Bitar C, Menge TD, Chan MP. Cutaneous manifestations of lupus erythematosus: A practical clinicopathological review for pathologists. Histopathology. 2022, 80:233-50. 10.1111\/his.14440","journal-title":"Histopathology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5048","article-title":"The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: A narrative review","volume":"9","author":"Chakka S","year":"2021","unstructured":"Chakka S, Krain RL, Concha JS, Chong BF, Merola JF, Werth VP. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: A narrative review. Ann Transl Med. 2021, 9:431. 10.21037\/atm-20-5048","journal-title":"Ann Transl Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13082419","article-title":"The spectrum of cutaneous manifestations in lupus erythematosus: A comprehensive review","volume":"13","author":"Fija\u0142kowska A","year":"2024","unstructured":"Fija\u0142kowska A, K\u0105dziela M, \u017bebrowska A. The spectrum of cutaneous manifestations in lupus erythematosus: A comprehensive review. J Clin Med. 2024, 13:2419. 10.3390\/jcm13082419","journal-title":"J Clin Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6610509","article-title":"Cutaneous manifestations of \u201cLupus\u201d: Systemic lupus erythematosus and beyond","volume":"2021","author":"Cooper EE","year":"2021","unstructured":"Cooper EE, Pisano CE, Shapiro SC. Cutaneous manifestations of \u201cLupus\u201d: Systemic lupus erythematosus and beyond. Int J Rheumatol. 2021, 2021:6610509. 10.1155\/2021\/6610509","journal-title":"Int J Rheumatol"},{"key":"ref32","article-title":"Discoid Lupus Erythematosus","author":"McDaniel B","year":"2024","unstructured":"McDaniel B, Sukumaran S, Koritala T, Tanner LS. Discoid Lupus Erythematosus. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220089","article-title":"Cutaneous involvement in systemic lupus erythematosus: A review for the rheumatologist","volume":"50","author":"Stull C","year":"2023","unstructured":"Stull C, Sprow G, Werth VP. Cutaneous involvement in systemic lupus erythematosus: A review for the rheumatologist. J Rheumatol. 2023, 50:27-35. 10.3899\/jrheum.220089","journal-title":"J Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S269288","article-title":"Recent insight on the management of lupus erythematosus alopecia","volume":"14","author":"Desai K","year":"2021","unstructured":"Desai K, Miteva M. Recent insight on the management of lupus erythematosus alopecia. Clin Cosmet Investig Dermatol. 2021, 14:333-47. 10.2147\/CCID.S269288","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2021.02.008","article-title":"Skin manifestations associated with systemic diseases - Part I","volume":"96","author":"Sampaio AL","year":"2021","unstructured":"Sampaio AL, Bressan AL, Vasconcelos BN, Gripp AC. Skin manifestations associated with systemic diseases - Part I. An Bras Dermatol. 2021, 96:655-71. 10.1016\/j.abd.2021.02.008","journal-title":"An Bras Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01353","article-title":"Current insights in cutaneous lupus erythematosus immunopathogenesis","volume":"11","author":"Garelli CJ","year":"2020","unstructured":"Garelli CJ, Refat MA, Nanaware PP, Ramirez-Ortiz ZG, Rashighi M, Richmond JM. Current insights in cutaneous lupus erythematosus immunopathogenesis. Front Immunol. 2020, 11:1353. 10.3389\/fimmu.2020.01353","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/834291","article-title":"Cutaneous manifestations of systemic lupus erythematosus","volume":"2012","author":"Uva L","year":"2012","unstructured":"Uva L, Miguel D, Pinheiro C, Freitas JP, Marques Gomes M, Filipe P. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis. 2012, 2012:834291. 10.1155\/2012\/834291","journal-title":"Autoimmune Dis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4166","article-title":"Pericarditis in lupus","volume":"11","author":"Dein E","year":"2019","unstructured":"Dein E, Douglas H, Petri M, Law G, Timlin H. Pericarditis in lupus. Cureus. 2019, 11:e4166. 10.7759\/cureus.4166","journal-title":"Cureus"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.206","article-title":"Cardiorheumatology: Cardiac involvement in systemic rheumatic disease","volume":"12","author":"Prasad M","year":"2015","unstructured":"Prasad M, Hermann J, Gabriel SE, et al.. Cardiorheumatology: Cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol. 2015, 12:168-76. 10.1038\/nrcardio.2014.206","journal-title":"Nat Rev Cardiol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26671","article-title":"Cardiovascular complications in systemic lupus erythematosus","volume":"14","author":"Alghareeb R","year":"2022","unstructured":"Alghareeb R, Hussain A, Maheshwari MV, Khalid N, Patel PD. Cardiovascular complications in systemic lupus erythematosus. Cureus. 2022, 14:e26671. 10.7759\/cureus.26671","journal-title":"Cureus"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01045-7","article-title":"Autoimmune diseases and atherosclerotic cardiovascular disease","volume":"21","author":"Porsch F","year":"2024","unstructured":"Porsch F, Binder CJ. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2024, 21:780-807. 10.1038\/s41569-024-01045-7","journal-title":"Nat Rev Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2017.09.012","article-title":"Atherosclerosis in systemic lupus erythematosus","volume":"31","author":"Croca S","year":"2017","unstructured":"Croca S, Rahman A. Atherosclerosis in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017, 31:364-72. 10.1016\/j.berh.2017.09.012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.870200","article-title":"Cardiac magnetic resonance in rheumatology to detect cardiac involvement since early and pre-clinical stages of the autoimmune diseases: A narrative review","volume":"9","author":"Sierra-Galan LM","year":"2022","unstructured":"Sierra-Galan LM, Bhatia M, Alberto-Delgado AL, et al.. Cardiac magnetic resonance in rheumatology to detect cardiac involvement since early and pre-clinical stages of the autoimmune diseases: A narrative review. Front Cardiovasc Med. 2022, 9:870200. 10.3389\/fcvm.2022.870200","journal-title":"Front Cardiovasc Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00941","article-title":"Cardiac manifestations of antiphospholipid syndrome with focus on its primary form","volume":"10","author":"Kolitz T","year":"2019","unstructured":"Kolitz T, Shiber S, Sharabi I, Winder A, Zandman-Goddard G. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol. 2019, 10:941. 10.3389\/fimmu.2019.00941","journal-title":"Front Immunol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"31","author":"Kuhn A","year":"2017","unstructured":"Kuhn A, Aberer E, Bata-Cs\u00f6rg\u0151 Z, et al.. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017, 31:389-404. 10.1111\/jdv.14053","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis A","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, et al.. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019, 78:736-45. 10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15312","article-title":"Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: A systematic review and meta-analysis","volume":"177","author":"Chasset F","year":"2017","unstructured":"Chasset F, Bouaziz JD, Costedoat-Chalumeau N, Franc\u00e8s C, Arnaud L. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: A systematic review and meta-analysis. Br J Dermatol. 2017, 177:188-96. 10.1111\/bjd.15312","journal-title":"Br J Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman MJ","year":"2003","unstructured":"Roman MJ, Shanker BA, Davis A, et al.. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003, 349:2399-406. 10.1056\/NEJMoa035471","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113469","article-title":"Cardiovascular protection of hydroxychloroquine in patients with Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Yang DH","year":"2020","unstructured":"Yang DH, Wang YH, Pan LF, Wei JC. Cardiovascular protection of hydroxychloroquine in patients with Sj\u00f6gren\u2019s syndrome. J Clin Med. 2020, 9:3469. 10.3390\/jcm9113469","journal-title":"J Clin Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.012","article-title":"Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure","volume":"52","author":"R\u00faa-Figueroa I","year":"2022","unstructured":"R\u00faa-Figueroa I, R\u00faa-Figueroa D, P\u00e9rez-Veiga N, et al.. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure. Semin Arthritis Rheum. 2022, 52:151946. 10.1016\/j.semarthrit.2021.11.012","journal-title":"Semin Arthritis Rheum"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut290","article-title":"Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus","volume":"16","author":"Teixeira RA","year":"2014","unstructured":"Teixeira RA, Borba EF, Pedrosa A, et al.. Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus. Europace. 2014, 16:887-92. 10.1093\/europace\/eut290","journal-title":"Europace"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D","article-title":"Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus","volume":"42","author":"Manzi S","year":"1999","unstructured":"Manzi S, Selzer F, Sutton-Tyrrell K, et al.. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999, 42:1-51. 10.1002\/1529-0131(199901)42:1&lt;51::AID-ANR7&gt;3.0.CO;2-D","journal-title":"Arthritis Rheum"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090306","article-title":"Risk factors for clinical coronary heart disease in systemic lupus erythematosus: The lupus and atherosclerosis evaluation of risk (LASER) study","volume":"37","author":"Haque S","year":"2010","unstructured":"Haque S, Gordon C, Isenberg D, et al.. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: The lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol. 2010, 37:322-9. 10.3899\/jrheum.090306","journal-title":"J Rheumatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13588","article-title":"Body mass index and glucocorticoid dose contribute to subclinical atherosclerosis in Korean patients with systemic lupus erythematosus: A prospective 4\u00a0year follow-up study","volume":"22","author":"Jung JY","year":"2019","unstructured":"Jung JY, Kim HA, Lee HY, Suh CH. Body mass index and glucocorticoid dose contribute to subclinical atherosclerosis in Korean patients with systemic lupus erythematosus: A prospective 4\u00a0year follow-up study. Int J Rheum Dis. 2019, 22:1410-8. 10.1111\/1756-185X.13588","journal-title":"Int J Rheum Dis"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311425524","article-title":"Cardiovascular event in systemic lupus erythematosus in northern Sweden: Incidence and predictors in a 7-year follow-up study","volume":"21","author":"Bengtsson C","year":"2012","unstructured":"Bengtsson C, Ohman ML, Nived O, Rantap\u00e4\u00e4 Dahlqvist S. Cardiovascular event in systemic lupus erythematosus in northern Sweden: Incidence and predictors in a 7-year follow-up study. Lupus. 2012, 21:452-9. 10.1177\/0961203311425524","journal-title":"Lupus"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190259","article-title":"Effect of disease activity on organ damage progression in systemic lupus erythematosus: University of Toronto Lupus Clinic cohort","volume":"48","author":"Urowitz MB","year":"2021","unstructured":"Urowitz MB, Gladman DD, Iba\u00f1ez D, et al.. Effect of disease activity on organ damage progression in systemic lupus erythematosus: University of Toronto Lupus Clinic cohort. J Rheumatol. 2021, 48:67-73. 10.3899\/jrheum.190259","journal-title":"J Rheumatol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep102","article-title":"Predictors of cardiovascular damage in patients with systemic lupus erythematosus: Data from LUMINA (LXVIII), a multiethnic US cohort","volume":"48","author":"Pons-Estel GJ","year":"2009","unstructured":"Pons-Estel GJ, Gonz\u00e1lez LA, Zhang J, Burgos PI, Reveille JD, Vil\u00e1 LM, Alarc\u00f3n GS. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: Data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford). 2009, 48:817-22. 10.1093\/rheumatology\/kep102","journal-title":"Rheumatology (Oxford)"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152226","article-title":"Factors associated with cardiovascular events in systemic lupus erythematosus in a monocentric cohort with up to 40 years of follow-up","volume":"61","author":"Farina N","year":"2023","unstructured":"Farina N, Webster J, Luo W, Garelick D, Pinto SM, Isenberg D, Rahman A. Factors associated with cardiovascular events in systemic lupus erythematosus in a monocentric cohort with up to 40 years of follow-up. Semin Arthritis Rheum. 2023, 61:152226. 10.1016\/j.semarthrit.2023.152226","journal-title":"Semin Arthritis Rheum"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.11.003","article-title":"Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 new cases and a literature review of 118 cases","volume":"48","author":"de Risi-Pugliese T","year":"2018","unstructured":"de Risi-Pugliese T, Aubart FA, Haroche J, et al.. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 new cases and a literature review of 118 cases. Semin Arthritis Rheum. 2018, 48:83-9. 10.1016\/j.semarthrit.2017.11.003","journal-title":"Semin Arthritis Rheum"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: Diagnosis and clinical management","volume":"96","author":"Fava A","year":"2019","unstructured":"Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2019, 96:1-13. 10.1016\/j.jaut.2018.11.001","journal-title":"J Autoimmun"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae192","article-title":"Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment","author":"Dedemadi AG","year":"2024","unstructured":"Dedemadi AG, Gkolfinopoulou C, Nikoleri D, et al.. Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment. Rheumatology (Oxford). 2024, keae192. 10.1093\/rheumatology\/keae192","journal-title":"Rheumatology (Oxford)"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez191","article-title":"Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus","volume":"58","author":"Parodis I","year":"2019","unstructured":"Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatology (Oxford). 2019, 58:2170-6. 10.1093\/rheumatology\/kez191","journal-title":"Rheumatology (Oxford)"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand EF","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al.. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020, 382:211-21. 10.1056\/NEJMoa1912196","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1002\/art.41518","article-title":"Modulation of cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus","volume":"73","author":"Casey KA","year":"2021","unstructured":"Casey KA, Smith MA, Sinibaldi D, et al.. Modulation of cardiometabolic disease markers by type I interferon inhibition in systemic lupus erythematosus. Arthritis Rheumatol. 2021, 73:459-71. 10.1002\/art.41518","journal-title":"Arthritis Rheumatol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa862","article-title":"Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications","volume":"60","author":"Choi MY","year":"2021","unstructured":"Choi MY, Li D, Feldman CH, et al.. Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications. Rheumatology (Oxford). 2021, 60:3789-98. 10.1093\/rheumatology\/keaa862","journal-title":"Rheumatology (Oxford)"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000472","article-title":"Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"8","author":"Wind M","year":"2021","unstructured":"Wind M, Hendriks M, van Brussel BT, et al.. Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and\/or antiphospholipid syndrome. Lupus Sci Med. 2021, 8:e000472. 10.1136\/lupus-2020-000472","journal-title":"Lupus Sci Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/324908-cutaneous-manifestations-of-systemic-lupus-erythematosus-and-their-correlation-with-cardiac-involvement","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T18:27:53Z","timestamp":1735324073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/324908-cutaneous-manifestations-of-systemic-lupus-erythematosus-and-their-correlation-with-cardiac-involvement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":66,"URL":"https:\/\/doi.org\/10.7759\/cureus.76478","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,27]]}}}